Ampol Profit Surges as Refining Margins Hit Record Highs 
China EV Stocks Slide as Door Handle Recall Hits 4.3 Million Vehicles 
Amazon to Expand Drone Delivery to 500 U.S. Locations 
Hanmi Pharm Soars 30% on $2.3 Billion Genentech Obesity Drug Deal 
Australia’s Big Four Banks Face Mortgage Slowdown as Valuations Draw Scrutiny 
Xiaomi Unveils Xring O3 Chip for Flagship Foldable Phone 
Google Expands Gemini Enterprise With AI Tools for Legal Sector 
Bathla Group Hires Administrators as Australia Housing Slump Deepens 
Nvidia Options Price in $280 Billion Earnings Swing 
SK Hynix Shares Fall as Workers Reject Wage Deal 
SEC Probes Banks Over Situational Awareness Hedge Fund Collapse 
Exxon, LyondellBasell Eye Shell’s $8 Billion U.S. Chemicals Assets 
J.P. Morgan Upgrades Diploma, Lifts Price Target to 8,250p 
SoftBank Plans Record $6.3 Billion Bond Sale to Fund OpenAI Investments 
Apple Cuts Over 200 Siri, Vision Pro Jobs in AI Shift 
Adidas, Puma Shares Fall as Dick’s Sporting Goods Cuts Outlook 
Shein Launches $1.77 Billion Hong Kong IPO After Years of Listing Delays 
Add as a preferred source on Google
MORRISTOWN, N.J., May 01, 2018 -- Pernix Therapeutics Holdings, Inc. (NASDAQ:PTX), a specialty pharmaceutical company, announced today that the Company will report financial results for the first quarter ended March 31, 2018, after the market close on Thursday, May 10, 2018. Pernix management will also host a conference call at 4:30pm Eastern Time to discuss the results.
| Date: | Thursday, May 10 | ||||||||
| Time: | 4:30 PM ET | ||||||||
| Toll free (U.S.): | 888-394-8218 | ||||||||
| International: | 323-701-0225 | ||||||||
| Conference ID: | 7026871 | ||||||||
| Webcast: | http://public.viavid.com/index.php?id=129150 | ||||||||
About Pernix Therapeutics
Pernix Therapeutics is a specialty pharmaceutical business with a focus on acquiring, developing and commercializing prescription drugs primarily for the U.S. market. The Company is currently focused on the therapeutic areas of Pain and Neurology, and has an interest in expanding into additional specialty segments. The Company promotes its branded products to physicians through its internal sales force and markets its generic portfolio through its wholly owned subsidiaries, Macoven Pharmaceuticals, LLC and Cypress Pharmaceutical, Inc.
To learn more about Pernix Therapeutics, visit www.pernixtx.com.
CONTACT
Investor Relations
Bob Yedid
LifeSci Advisors, LLC
[email protected]
